Bicara Therapeutics (BCAX) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to ficerafusp alfa in combination with pembrolizumab for the first line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma, HNSCC, whose tumors express programmed death-ligand 1 with combined positive score greater than or equal to1, excluding human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Bicara Therapeutics files $400M mixed securities shelf
- Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
- Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
- Bicara Therapeutics initiated with a Buy at JonesResearch
- Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright